Importance Evidence of the efficacy and safety of messenger RNA (mRNA) COVID-19
vaccines in children aged 5 to 11 years has been emerging. Collecting these data will inform …

Efforts to control the COVID-19 pandemic have expanded to the vaccination of children and
adolescents. This systematic review assesses the utility of the BNT162b2 (Pfizer-BioNTech) …

Purpose The validity of the diagnosis codes to identify myocarditis cases in healthcare
databases research remains unclear, and this study aimed to determine the coding accuracy …

Objective To review whether the current COVID-19 vaccines can prevent the occurrence of
multisystem inflammatory syndrome in children (MIS-C) and adolescents. Methods A …

During the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), mitigation policies for children have been a topic of considerable uncertainty and …

Objectives We estimated the BNT162b2 vaccine effectiveness (VE) against any
(symptomatic or not) SARS-CoV-2 Delta and Omicron infection among adolescents (aged …

Methods This prospective population-based cohort study included patients aged 5 to 11
years fulfilling the case definition for myocarditis and/or pericarditis following Pfizer …

Several immunization products are currently being developed against respiratory syncytial
virus (RSV) for children, pregnant females, and older adults, and some products have …

Objectives The aims of this cross-sectional study were to investigate why parents decide to
vaccinate, as well as the determinants, their children aged 5-11 years against COVID-19 in …

Background The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been
authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but …